ClinicalTrials.gg
Not yet recruitingNCT07936084Updated Nov 13, 2026

Clinical Trial of GenSci136 in Patients With Myasthenia Gravis

A Phase 1/2 interventional study of GenSci136 for injection in Patients With MG (gMG and oMG), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Phase Ib/II Clinical Trial of GenSci136 in Patients with Myasthenia Gravis

Read the detailed description

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Trial (Including an Open-Label Extension Phase) to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of GenSci136 for Injection in Patients with Myasthenia Gravis

02

Conditions studied

  • Patients With MG (gMG and oMG)
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 70 years (both inclusive).
  2. standard-of-care (SoC) treatment for MG before screening.
  3. Men of reproductive age and women of must agree to take highly effective methods from screening to 5 months after the last dose4. Participants who can understand the trial procedures, voluntarily participate in the trial (themselves or through their legally acceptable representative), For participants with gMG: 1. Participants diagnosed with gMG with generalized muscle weakness, corresponding to Myasthenia Gravis Foundation of America (MGFA) clinical classification Class II-IV

2. Positive for anti-AChR antibodies or anti-MuSK antibodies. 3. MG-ADL score must be ≥ 6, and the ocular score must account for \< 50% of the total score. 4. QMG score must be ≥ 8, with at least 4 individual items scored ≥ 2. For participants with oMG: 1. Participants with a diagnosis of MG supported by the following medical documentation: a. Positive anti-AChR or anti-MuSK autoantibodies; or b. Abnormal neuromuscular transmission confirmed by single-fiber electromyography (SFEMG)/repetitive nerve stimulation (RNS), together with at least one of the following pharmacological/clinical confirmations: 1) documented positive ice pack test (resolution of ptosis after application of an ice pack to the eyelid for 2 minutes, with an improvement of > 2 mm); 2) documented positive edrophonium chloride (Tensilon) test, or a positive test with another cholinesterase inhibitor currently used in clinical practice to confirm oMG, such as the neostigmine test; or 3) documented improvement in MG signs following treatment with oral AChE inhibitors, plasma exchange, IVIg, , or other relevant therapies. 2. Participants diagnosed with oMG, corresponding to MGFA clinical classification Class I. 3. the MGII (PRO) ocular score must be ≥ 6, and at least 2 ocular items must have a score of ≥ 2. 4. No pupillary abnormalities, except those caused by previous localized disease or surgery.

Exclusion criteria

Exclusion Criteria:

  1. Known to GenSci136 or any of the contained in the GenSci136 formulation, or history of serious hypersensitivity reactions to any drug
  2. Participants with diseases or dysfunctions (excluding MG) known to interfere with the clinical trial,
  3. Participants with a known history of malignant tumors (including but not limited to lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, prostate cancer, thyroid cancer, bladder cancer, pancreatic cancer, kidney cancer, breast cancer, cervical cancer, corpus uteri cancer, ovarian cancer and malignant melanoma) are excluded unless they have been free of recurrence for ≥ 3 years; basal cell carcinoma, non- squamous cell carcinoma of the skin, cervical carcinoma in situ, breast carcinoma in situ, and incidental prostate cancer T1a/T1b are not excluded under this criterion (for thymoma-related requirements, see Exclusion Criterion 8).
  4. Presence of acute or chronic infections requiring treatment at screening.
  5. History of MG crisis within 1 month before screening.
  6. Diagnosis of any other disease at screening other than MG, e.g., rheumatoid arthritis, Sjögren's syndrome (patients with abnormal thyroid function at screening will be excluded; those with autoimmune thyroiditis under stable control for ≥ 6 months and with normal thyroid function at screening may be exempted). 7. Participants who have attempted suicide within the past year or are currently at risk of impulsive behavior or suicide. 8. Participants with current or prior thymoma or thymectomy (except those meeting the criteria specified below), or planned thymectomy during the trial period. 9. Receipt of any live or within 1 month before screening, or planned receipt of any live or live attenuated vaccine (except inactivated vaccine) during the trial period. 10. Receipt of intravenous, subcutaneous, or intramuscular immunoglobulin or plasma exchange within 1 month before screening. 11. Treatment with any form of CAR-T cell therapy, T-cell engager (TCE) therapy, or biologics targeting CD19/CD20 within 1 year before screening. 12. Positive virus at screening [hepatitis B surface antigen (HBsAg) positive; or HBsAg negative with hepatitis B core antibody (HBcAb) positive and hepatitis B virus deoxyribonucleic acid (HBV-DNA) positive or > (ULN)], positive virus antibody (HCV-Ab), positive antibody (HIV-Ab), or positive syphilis serology test. 13. 12-lead abnormalities during the screening period or at baseline, e.g., heart rate- interval QTcF absolute value > 470 ms (Fridericia's formula: QTcF = QT/RR0.33) that, upon assessment by the investigator, may interfere with this clinical trial. 14. During the screening or baseline period, participants with any of the following abnormal laboratory test results: a) (ANC) \< 1.2 × 10³/μL ; b) count \< 75,000/μL (i.e., \< 75 × 10⁹/L); c) \< 8.0 g/dL; d) IgG \< 600 mg/dL; e) Creatinine > 1.5 × ULN or estimated (eGFR) \< 60 mL/min/1.73 m2; f) (HbA1c) > 8.0%, except for participants whose blood glucose control is considered adequate by the investigator; g) (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN), or total (TBIL) > 1.5 × ULN; h) Other abnormal laboratory test results deemed by the investigator to make the participant unsuitable for participation in the study. 15. Participants judged by the investigator to be ineligible for other reasons.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    GenSci136 for injection

    Drug: GenSci136 for injection

  • Placebo comparator
    GenSci136 blank excipient(placebo) for injection

    Drug: GenSci136 for injection

Interventions

  • DrugGenSci136 for injection

    GenSci136 for injection, administered the medication according to the requirements of the protocal

06

What researchers measure

Primary outcomes

  1. Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).

    Time frame: From time of informed consent to 10 weeks after the first dose of GenSci136

  2. Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).

    Time frame: Approximately 26 weeks

Secondary outcomes

  1. area under the concentration-time curve from time 0 to time t of the last quantifiable concentration (AUC0-t)

    Time frame: Approximately 10 weeks.

  2. area under the concentration-time curve from time 0 to infinity (AUC0-∞)

    Time frame: Approximately 10 weeks

  3. area under the concentration-time curve from time 0 to time τ (AUC0-τ)

    Time frame: Approximately 10 weeks

  4. maximum concentration (Cmax)

    Time frame: Approximately 10 weeks

  5. time to maximum concentration (Tmax)

    Time frame: Approximately 10 weeks

  6. apparent clearance (CL/F)

    Time frame: Approximately 10 weeks

  7. apparent volume of distribution (Vd/F)

    Time frame: Approximately 10 weeks

  8. Changes from baseline in free and total A proliferation-inducing ligand (APRIL) levels

    Time frame: Approximately 10 weeks

  9. Changes from baseline in free and total B-cell activating factor (BAFF) levels

    Time frame: Approximately 10 weeks

  10. Change from baseline in MG-ADL score at Week 48

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24. Higher scores indicate greater disease severity and worse functional status.

    Time frame: Approximately 48 Weeks

  11. Proportion of participants with a ≥ 2-point reduction from baseline in MG-ADL score at Week 26 and Week 48

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24. Higher scores indicate greater disease severity and worse functional status.

    Time frame: Approximately 48 Weeks

  12. Proportion of participants with a ≥ 3-point reduction from baseline in QMG score at Week 26 and Week 48

    The Quantitative Myasthenia Gravis (QMG) score is a 13-item clinician-administered measure used to assess muscle weakness and disease severity in patients with myasthenia gravis. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 39. Higher scores indicate greater disease severity and worse clinical outcomes.

    Time frame: Approximately 48 Weeks

  13. Proportion of participants with minimal symptom expression (MSE, MG-ADL score of 0 or 1) at Week 26 and Week 48

    Minimal symptom expression (MSE) is defined as a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score of 0 or 1. The MG-ADL is an 8-item scale used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24, with higher scores indicating greater disease severity and worse functional status.

    Time frame: Approximately 48 Weeks

  14. Change from baseline in total Myasthenia Gravis Composite (MGC) score at Week 26 and Week 4

    The Myasthenia Gravis Composite (MGC) is a validated 10-item assessment tool used to evaluate the clinical severity of myasthenia gravis, incorporating both physician-assessed and patient-reported measures. The total score ranges from 0 to 50, with higher scores indicating greater disease severity and worse clinical outcomes

    Time frame: Approximately 26 Weeks

  15. Change from baseline in Revised Myasthenia Gravis Quality of Life-15 (MG-QoL15r) score at Week 26 and Week 48

    The Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) is a patient-reported questionnaire used to assess the impact of myasthenia gravis on health-related quality of life. It consists of 15 items, each scored from 0 to 2, resulting in a total score ranging from 0 to 30. Higher scores indicate greater impairment in quality of life and worse clinical outcomes.

    Time frame: Approximately 48 Weeks

  16. Change from baseline in EuroQol Five-Dimension Five-Level (EQ-5D-5L) score at Week 26 and Week 48

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire is a standardized measure of health-related quality of life comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, ranging from 1 (no problems) to 5 (extreme problems). Responses are converted into a health utility index. The EQ Visual Analogue Scale (EQ-VAS) assesses participants' self-rated overall health status on a scale from 0 (worst imaginable health) to 100 (best imaginable health). Higher Index and EQ-VAS scores indicate better health status.

    Time frame: Approximately 48 Weeks

  17. Change from baseline in MG-ADL score over time

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess the impact of myasthenia gravis symptoms on daily activities. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 24. Higher scores indicate greater disease severity and worse functional status.

    Time frame: Approximately 48 Weeks

  18. Change from baseline in QMG score over time

    The Quantitative Myasthenia Gravis (QMG) score is a 13-item clinician-administered measure used to assess muscle weakness and disease severity in patients with myasthenia gravis. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 39. Higher scores indicate greater disease severity and worse clinical outcomes.

    Time frame: Approximately 48 Weeks

  19. Change from baseline in MGC score over time

    The Myasthenia Gravis Composite (MGC) is a validated 10-item assessment tool used to evaluate the clinical severity of myasthenia gravis, incorporating both physician-assessed and patient-reported measures. The total score ranges from 0 to 50, with higher scores indicating greater disease severity and worse clinical outcomes.

    Time frame: Approximately 48 Weeks

  20. Change from baseline in MG-QoL15r score over time

    The Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) is a patient-reported questionnaire used to assess the impact of myasthenia gravis on health-related quality of life. It consists of 15 items, each scored from 0 to 2, resulting in a total score ranging from 0 to 30. Higher scores indicate greater impairment in quality of life and worse clinical outcomes.

    Time frame: Approximately 48 Weeks

  21. Change from baseline in EQ-5D-5L score over time

    The EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire is a standardized measure of health-related quality of life comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, ranging from 1 (no problems) to 5 (extreme problems). Responses are converted into a health utility index. The EQ Visual Analogue Scale (EQ-VAS) assesses participants' self-rated overall health status on a scale from 0 (worst imaginable health) to 100 (best imaginable health). Higher Index and EQ-VAS scores indicate better health status.

    Time frame: Approximately 48 Weeks

  22. Change from baseline in ocular score of the Myasthenia Gravis Impairment Index (participant-reported outcomes) [MGII (PRO)] at Week 26 and Week 48

    The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising 22 patient-reported outcome (PRO) items and 6 physical examination (PE) items. The MGII ocular PRO score consists of 6 patient-reported items assessing the frequency, severity, and impact of diplopia and ptosis. Each item is scored from 0 to 3, yielding a total ocular PRO score ranging from 0 to 18. Higher scores indicate more severe ocular symptoms.

    Time frame: Approximately 48 weeks

  23. Change from baseline in ocular score of the Myasthenia Gravis Impairment Index (Participant-reported Outcome and Physical Examination) (MGII [PRO+PE]) at Week 26 and Week 48

    The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising 22 patient-reported outcome (PRO) items and 6 physical examination (PE) items. The MGII ocular PRO+PE score combines 6 patient-reported items and 2 clinician-assessed physical examination items evaluating diplopia and ptosis. The score is calculated as the sum of these 8 items, ranging from 0 to 23. Higher scores indicate more severe ocular impairment

    Time frame: Approximately 48 weeks

  24. Change from baseline in ocular score of the MGII (PE) at Week 26 and Week 48

    The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising patient-reported and physical examination components. The MGII ocular physical examination (PE) score consists of 2 clinician-assessed items evaluating diplopia (scored from 0 to 3) and ptosis (scored from 0 to 2). The total ocular PE score ranges from 0 to 5, with higher scores indicating more severe ocular impairment.

    Time frame: Approximately 48 weeks

  25. Changes from baseline in total MGII score at Week 26 and Week 48

    Time frame: Approximately 48 weeks

  26. Changes from baseline in the incidence and severity of TEAEs

    The Myasthenia Gravis Impairment Index (MGII) is a validated measure of myasthenia gravis disease severity comprising 28 items, including 22 patient-reported outcome (PRO) items and 6 physical examination (PE) items. The MGII evaluates ocular and generalized impairments, including symptoms affecting ocular, bulbar, respiratory, and limb muscle function. The total score is calculated as the sum of all 28 items and ranges from 0 to 84. Higher scores indicate greater disease severity and impairment.

    Time frame: Approximately 64 weeks

  27. Changes from baseline in the incidence and severity of SAEs

    Time frame: Approximately 64 weeks

  28. steady-state maximum concentration (Cmax, ss)

    Time frame: Approximately 64 weeks

  29. steady-state trough concentration (Cmin, ss)

    Time frame: Approximately 64 weeks

  30. time to steady-state maximum concentration (Tmax, ss)

    Time frame: Approximately 64 weeks

  31. mean concentration at steady state (Cav, ss)

    Time frame: Approximately 64 weeks

  32. area under the concentration-time curve over the dosing interval at steady state (AUC0-τ, ss)

    Time frame: Approximately 64 weeks

  33. Changes from baseline in free and total APRIL levels

    Time frame: Approximately 64 weeks

  34. Changes from baseline in free and total BAFF levels

    Time frame: Approximately 64 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 13, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07936084
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Chongbo Zhao
Contact
zhao_chongbo@fudan.edu.com
+86 13701822316
Sushan Luo
principal investigator · Huashan Hospital
Bitao Bu
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion